Literature DB >> 23440719

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

Kevin M Flanigan1, Ermelinda Ceco, Kay-Marie Lamar, Yuuki Kaminoh, Diane M Dunn, Jerry R Mendell, Wendy M King, Alan Pestronk, Julaine M Florence, Katherine D Mathews, Richard S Finkel, Kathryn J Swoboda, Eduard Gappmaier, Michael T Howard, John W Day, Craig McDonald, Elizabeth M McNally, Robert B Weiss.   

Abstract

OBJECTIVE: Duchenne muscular dystrophy (DMD) displays a clinical range that is not fully explained by the primary DMD mutations. Ltbp4, encoding latent transforming growth factor-β binding protein 4, was previously discovered in a genome-wide scan as a modifier of murine muscular dystrophy. We sought to determine whether LTBP4 genotype influenced DMD severity in a large patient cohort.
METHODS: We analyzed nonsynonymous single nucleotide polymorphisms (SNPs) from human LTBP4 in 254 nonambulatory subjects with known DMD mutations. These SNPs, V194I, T787A, T820A, and T1140M, form the VTTT and IAAM LTBP4 haplotypes.
RESULTS: Individuals homozygous for the IAAM LTBP4 haplotype remained ambulatory significantly longer than those heterozygous or homozygous for the VTTT haplotype. Glucocorticoid-treated patients who were IAAM homozygotes lost ambulation at 12.5 ± 3.3 years compared to 10.7 ± 2.1 years for treated VTTT heterozygotes or homozygotes. IAAM fibroblasts exposed to transforming growth factor (TGF) β displayed reduced phospho-SMAD signaling compared to VTTT fibroblasts, consistent with LTBP4' role as a regulator of TGFβ.
INTERPRETATION: LTBP4 haplotype influences age at loss of ambulation, and should be considered in the management of DMD patients.
Copyright © 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440719      PMCID: PMC4106425          DOI: 10.1002/ana.23819

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  27 in total

1.  TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements.

Authors:  T G Hullinger; Q Pan; H L Viswanathan; M J Somerman
Journal:  Exp Cell Res       Date:  2001-01-01       Impact factor: 3.905

2.  Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta.

Authors:  J Saharinen; J Keski-Oja
Journal:  Mol Biol Cell       Date:  2000-08       Impact factor: 4.138

3.  Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation.

Authors:  E M McNally; M R Passos-Bueno; C G Bönnemann; M Vainzof; E de Sá Moreira; H G Lidov; K B Othmane; P H Denton; J M Vance; M Zatz; L M Kunkel
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

4.  Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.

Authors:  K M Dent; D M Dunn; A C von Niederhausern; A T Aoyagi; L Kerr; M B Bromberg; K J Hart; T Tuohy; S White; J T den Dunnen; R B Weiss; K M Flanigan
Journal:  Am J Med Genet A       Date:  2005-04-30       Impact factor: 2.802

5.  Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.

Authors:  Y-W Chen; K Nagaraju; M Bakay; O McIntyre; R Rawat; R Shi; E P Hoffman
Journal:  Neurology       Date:  2005-08-10       Impact factor: 9.910

6.  Genetic association analysis of functional impairment in chronic obstructive pulmonary disease.

Authors:  Craig P Hersh; Dawn L Demeo; Ross Lazarus; Juan C Celedón; Benjamin A Raby; Joshua O Benditt; Gerard Criner; Barry Make; Fernando J Martinez; Paul D Scanlon; Frank C Sciurba; James P Utz; John J Reilly; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

7.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

8.  Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation.

Authors:  M Kefi; R Amouri; A Driss; C Ben Hamida; M Ben Hamida; L M Kunkel; F Hentati
Journal:  Neuromuscul Disord       Date:  2003-12       Impact factor: 4.296

9.  Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.

Authors:  P Bernasconi; E Torchiana; P Confalonieri; R Brugnoni; R Barresi; M Mora; F Cornelio; L Morandi; R Mantegazza
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

10.  BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein.

Authors:  Gaoxiang Ge; Daniel S Greenspan
Journal:  J Cell Biol       Date:  2006-10-02       Impact factor: 10.539

View more
  104 in total

1.  Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.

Authors:  Utkarsh J Dang; Michael Ziemba; Paula R Clemens; Yetrib Hathout; Laurie S Conklin; Eric P Hoffman
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

2.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

3.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

Review 4.  Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.

Authors:  Elisabeth Le Rumeur
Journal:  Bosn J Basic Med Sci       Date:  2015-07-20       Impact factor: 3.363

5.  A healthy tension in translational research.

Authors:  Harry Dietz
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

6.  Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.

Authors:  Hannah R Spaulding; Tiffany Quindry; Kayleen Hammer; John C Quindry; Joshua T Selsby
Journal:  J Appl Physiol (1985)       Date:  2019-07-11

7.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.

Authors:  Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

Review 8.  Modifiers of heart and muscle function: where genetics meets physiology.

Authors:  Kayleigh A Swaggart; Elizabeth M McNally
Journal:  Exp Physiol       Date:  2013-11-08       Impact factor: 2.969

9.  Dusp6 is a genetic modifier of growth through enhanced ERK activity.

Authors:  Andy H Vo; Kayleigh A Swaggart; Anna Woo; Quan Q Gao; Alexis R Demonbreun; Katherine S Fallon; Mattia Quattrocelli; Michele Hadhazy; Patrick G T Page; Zugen Chen; Ascia Eskin; Kevin Squire; Stanley F Nelson; Elizabeth M McNally
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

10.  DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Lauren P Morgenroth; Heather Gordish-Dressman; Eric P Hoffman; Craig M McDonald; Sebahattin Cirak
Journal:  Neurology       Date:  2016-06-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.